MA48936A - Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques - Google Patents

Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Info

Publication number
MA48936A
MA48936A MA048936A MA48936A MA48936A MA 48936 A MA48936 A MA 48936A MA 048936 A MA048936 A MA 048936A MA 48936 A MA48936 A MA 48936A MA 48936 A MA48936 A MA 48936A
Authority
MA
Morocco
Prior art keywords
vitamin
ester
treating bacterial
formulation based
fungal biofilms
Prior art date
Application number
MA048936A
Other languages
English (en)
Other versions
MA48936B1 (fr
Inventor
Giorgio Panin
Original Assignee
Bio Lo Ga Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Lo Ga Srl filed Critical Bio Lo Ga Srl
Publication of MA48936A publication Critical patent/MA48936A/fr
Publication of MA48936B1 publication Critical patent/MA48936B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
MA48936A 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques MA48936B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT102017000058311A IT201700058311A1 (it) 2017-05-29 2017-05-29 Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
PCT/EP2018/063926 WO2018219862A1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Publications (2)

Publication Number Publication Date
MA48936A true MA48936A (fr) 2020-04-08
MA48936B1 MA48936B1 (fr) 2022-08-31

Family

ID=60294053

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48936A MA48936B1 (fr) 2017-05-29 2018-05-28 Formulation à base de vitamine e ou d'un ester de celle-ci pour traiter les biofilms bactériens et fongiques

Country Status (24)

Country Link
US (3) US20200360339A1 (fr)
EP (1) EP3630092B1 (fr)
CN (1) CN110650737A (fr)
AU (1) AU2018275487B2 (fr)
BR (1) BR112019023962A8 (fr)
CA (1) CA3061568C (fr)
CL (1) CL2019003254A1 (fr)
CY (1) CY1125414T1 (fr)
DK (1) DK3630092T3 (fr)
EA (1) EA201992190A1 (fr)
ES (1) ES2919423T3 (fr)
GE (2) GEAP202015201A (fr)
HR (1) HRP20220808T1 (fr)
HU (1) HUE059185T2 (fr)
IT (1) IT201700058311A1 (fr)
LT (1) LT3630092T (fr)
MA (1) MA48936B1 (fr)
MX (1) MX389883B (fr)
PL (1) PL3630092T3 (fr)
PT (1) PT3630092T (fr)
RS (1) RS63347B1 (fr)
SI (1) SI3630092T1 (fr)
SM (1) SMT202200274T1 (fr)
WO (1) WO2018219862A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini
WO2021228849A1 (fr) * 2020-05-11 2021-11-18 Katholieke Universiteit Leuven Utilisation d'acides di- et tricarboxyliques gras dans la prévention de la formation d'un biofilm

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
JPH09169643A (ja) * 1995-12-22 1997-06-30 Sekisui Chem Co Ltd 寄生性皮膚疾患治療用外用剤
IT1302275B1 (it) * 1998-09-25 2000-09-05 Giorgio Panin Formulazione di gel idrofobo a base di vitamina e acetato perapplicazione topica.
EP3406244B1 (fr) * 2009-04-15 2023-06-07 BMG Pharma S.p.A. Compositions comprenant du gluconate de zinc et de la taurine pour les troubles muqueux ou dermiques
ITUB20153889A1 (it) * 2015-09-25 2017-03-25 Bio Lo Ga Srl Gel idrofobico a base di vitamina E esente da prodotti siliconici per applicazione topica
ITUB20169882A1 (it) * 2016-01-08 2017-07-08 Flame S R L Vitamina E per l’uso nel trattamento e nella prevenzione delle infezioni da biofilm.
IT201700058311A1 (it) * 2017-05-29 2018-11-29 Bio Lo Ga Srl Formulazione a base di vitamina E o di un suo estere per il trattamento di biofilm batterici e fungini

Also Published As

Publication number Publication date
AU2018275487B2 (en) 2024-03-14
CY1125414T1 (el) 2025-05-09
GEP20207179B (en) 2020-11-10
DK3630092T3 (da) 2022-06-20
HUE059185T2 (hu) 2022-10-28
US11234958B2 (en) 2022-02-01
BR112019023962A8 (pt) 2022-07-05
MA48936B1 (fr) 2022-08-31
SMT202200274T1 (it) 2022-07-21
IT201700058311A1 (it) 2018-11-29
US20200360339A1 (en) 2020-11-19
US20200121638A1 (en) 2020-04-23
AU2018275487A1 (en) 2019-11-07
WO2018219862A1 (fr) 2018-12-06
CN110650737A (zh) 2020-01-03
CA3061568A1 (fr) 2018-12-06
EP3630092B1 (fr) 2022-04-13
RS63347B1 (sr) 2022-07-29
PL3630092T3 (pl) 2022-09-12
HRP20220808T1 (hr) 2022-09-30
MX2019013559A (es) 2022-02-03
GEAP202015201A (en) 2020-07-27
CA3061568C (fr) 2024-02-13
US20210228541A1 (en) 2021-07-29
SI3630092T1 (sl) 2022-08-31
MX389883B (es) 2025-03-20
EP3630092A1 (fr) 2020-04-08
LT3630092T (lt) 2022-06-27
ES2919423T3 (es) 2022-07-26
EA201992190A1 (ru) 2020-09-03
GEAP201815201A (fr) 2020-07-27
CL2019003254A1 (es) 2020-07-03
BR112019023962A2 (pt) 2020-06-09
PT3630092T (pt) 2022-06-02

Similar Documents

Publication Publication Date Title
EP3735625A4 (fr) Navigation de robot et suivi d'objet
EP3843704A4 (fr) Formulations d'émulsion d'inhibiteurs de multikinase
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA46466A (fr) Formulations pharmaceutiques de protéines à viscosité réduite
MA51747A (fr) Formulation d'anticorps pharmaceutique à ph faible
EP3880685A4 (fr) Inhibiteurs d'arg1 et/ou d'arg2
EP3804389A4 (fr) Détermination et publication dynamiques d'amf de secours
EP3374350A4 (fr) Composés à base d'hydroxypyridinone et d'hydroxypyrimidinone pour le traitement d'infections bactériennes
EP3305292A4 (fr) Composition pharmaceutique d'inhibiteur de mek et procédé de préparation de celle-ci
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3442584A4 (fr) Combinaisons de conjugués anticorps-médicament à base de pbd et d'inhibiteurs de bcl-2
EP3621656A4 (fr) Formulation pour l'administration d'un médicament pour les yeux
MA54448A (fr) Dérivés naphthyridine et quinoléine en tant qu'inhibiteurs de alk5
EP3463405A4 (fr) Polythérapie à base d'adénovirus et d'immunomodulateurs
EP3413928A4 (fr) Agents thérapeutiques à base de micro-arn anti-angiogéniques pour l'inhibition de la néovascularisation cornéenne
MA54052A (fr) Formulation d'anticorps
EP3609864A4 (fr) Inhibiteurs de hdac6 et agents d'imagerie
EP3625262A4 (fr) Immunoconjugués anti-folr1 et combinaisons d'anticorps anti-pd-1
MA54139A (fr) Formulation d'anticorps
MA45226A (fr) Compositions et méthodes de traitement ou de prévention d'affections liées à l'oxalate
EP3413909A4 (fr) Administration sous-cutanée d'adénovirus à double ciblage
EP3600272A4 (fr) Agents permettant d'augmenter la sécrétion des glandes lipidique de meibomius
MA46641A (fr) Méthodes et compositions permettant d'empêcher la transmission de maladies propagées par un vecteur
EP3746058A4 (fr) Compositions et méthodes d'amélioration de la biodisponibilité de 5-hydroxytryptophane
EP3897593A4 (fr) Formulations de cannabinoïdes et compositions pharmaceutiques